Showing 1406 results
-
Press release /New leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury'…
-
Press release /New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
-
Press release /Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] …
-
Press release /Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
-
Press release /New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Press release /Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
-
Ad hoc release /Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
-
Ad hoc release /Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
-
Press release /Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading…